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Abstract
Paragangliomas represent only 10% of chromaffin tissue tumors and those arising from the mesentery seem to be
a rare occurrence. We report a case of a 55 year old man in whom an abdominal mass was discovered fortuitously
by ultrasonography during a routine health exam. He presented occasional heart palpitations and diaphoresis as
well as a well-demarcated mass upon abdominal physical examination. CT scan revealed a solid polylobulated
mass in the right lower quadrant. Exploration laparotomy revealed a voluminous multi-nodular tumoral mass,
which contained hemorrhagic spots. Histopathological studies confirmed the presence of a paraganglioma. The
excision of the mass as well as the surrounding intestine and mesentery also revealed two lymphatic metastases,
the first among 14 documented cases to be described concerning mesenteric paragangliomas. One year follow up
and CT scan revealed neither recurrence nor the presence of distant metastases.
Background
With an annual incidence estimated at 1/100,000, para-
gangliomas represent ten percent of catecholamine
secreting tumors. Paragangliomas arise from chromaffin
tissue most commonly found in the Zuckerkandl body,
the sympathetic plexus of the urinary bladder, the kid-
neys, and the heart or in the sympathetic ganglia of the
head or neck [1]. Some paragangliomas have been
described in the Gastrointestinal System, the majority of
which were associated with the duodenum. Only a very
select few were described to arise from the mesentery
[2]. Given their catecholamine secreting properties,
paragangliomas have the potential to present as a mass
with paroxystic symptoms of palpitations, pallor, tremor,
headache and diaphoresis as well as hypertension [3].
This however is only the case in 25% of the paraganglio-
mas. The rest have presented as abdominal masses with
or without hypertension [2]. After a thorough review of
the literature, this case report represents only the 14th
case of a mesenteric paraganglioma and the first to
document lymph node metastasis, a seemingly rare and
unusual occurrence [Table 1].
Case presentation
A 55-year-old man followed and treated for acid reflux
and dyslipidemia as well as resection of a cutaneous
sebaceous cyst, was admitted in our institution for the
investigation of an abdominal mass discovered fortui-
tously during a routine annual abdominal ultrasound.
The ultrasound, which revealed an asymptomatic hypoe-
chogenous polylobulated solid mass in the right
supraumbilical territory, was followed up and confirmed
with a CT scan (Figure 1). The mass was also evident
upon palpation of the right flanc, which revealed a well
circumscribed mass measuring roughly 10 cm in dia-
meter. Since a percutaneous biopsy was not possible,
the patient underwent an exploratory laparotomy with
resection of the mass (Figure 2) in question along with a
segment of the small intestine followed by primary ana-
stomosis. The post-operative course was uneventful.
The resected specimen consisted of segment of small
intestine measuring 30 cm in length, accompanied by a
small portion of adipo-fibrous mesenteric tissue. With the
mesenteric tissue was a voluminous multi-nodular tumoral
mass, measuring 11.5 × 9.5 × 6.5 cm. Upon further dissec-
tion of the solid mass, hemorrhagic spots were uncovered,
which were well demarcated in the periphery.
Histologic examination revealed a solid cellular prolif-
eration with an alveolar and focally diffuse architecture.
Groups of cells were separated by fibrovascular septae,
giving a characteristic “zellballen” nested appearance.
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with granular amphophilic cytoplasm. Nuclei were
round to oval in appearance with moderate atypia and
prominent nucleoli. The mitotic count and proliferative
indices were low (< 3/high power field and < 2%,
respectively). (Figure 3) No vascular invasion or necrosis
was noted. Nevertheless, local invasion was present with
extension into peripheral adipose tissue and two metas-
tases out of 9 resected lymph nodes were identified.
Immunohistochemical staining was positive for
Table 1 Documented data from 9 previous cases of mesenteric paragangliomas
NO of
case
First
Author
Year Age/
Sex
Symptoms Size (cm) Preoperative
Diagnosis
Surgical Procedures Mets Follow
up
1 Arean [11] 1956 32/M Abdominal mass
Nausea
Vomiting
Diarrhea
10 Abdominal Mass Resection of intestine and
mesentery along with mass
0N D
2 Carmichael
[12]
1970 62/F Abdominal mass
Hypertension
3.2 Abdominal Mass Resection of intestine and
mesentery along with mass
0N D
3 Tanaka [13] 1991 29/F Nausea
Vomiting
10 × 9 × 7 Retroperitoneal
mass
Resection of the mass Liver Alive
4 Onoue [14] 1999 38/F Free 4.5 × 3.2 × 3.0 Mesenteric Mass
HCC
Resection of intestine and
mesentery along with mass
Liver resection
0 Alive
5 Jaffer [5] 2002 76/M Hypertension 8.5 × 8.0 × 2.0 Abdominal Mass Resection of intestine and
mesentery along with mass
0N D
6 Muzaffar [2] 2002 76/M Abdominal Mass 20 × 15 Abdominal Mass ND 0 Alive
7 Kudoh [4] 2004 72/F Abdominal pain
and mass
10 × 10 × 9 Mesenteric
tumor
Resection of intestine and
mesentery along with mass
0 Alive
8 Svajdler
[15]
2007 65/M 10 × 8 0 Alive
9 Na Guo [7] 2009 22/F None 11.5 × 6.0 × 11.5 Resection of mass 0 Alive
10 Present
Case
2011 55/M Abdominal Mass 11.5 × 9.5 × 6.5 Resection of intestine and
mesentery along with mass
2 LN Alive,
56M
Figure 1 Contrast Enhanced Tomography of the abdominal mass under investigation. Contrast enhanced computer tomography scan
showed a polylobulated mass measuring 10.1 × 7 cm in right hemiabdomen and right lower quadrant.
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strating sustentacular cells around the periphery of the
cell nests. Based on histologic and immunohistochemical
features, a diagnosis of metastatic paraganglioma was
proposed (Figure 4).
Given the presence of a paraganglioma, a urinary
search for catecholamines and its derivatives was con-
ducted and was unremarkable post operatively.
Throughout the procedure, and well before the identi-
fication of the mass, the patient remained asymptomatic
Figure 3 Haematoxyin and Eosin staining of the resected specimen. Groups of cells were separated by fibrovascular septae, giving a
characteristic “zellballen” nested appearance. The group of cells were composed of polyhedral cells with granular amphopilic cytoplasm.
Figure 2 Abdominal Mass In Vivo. Multinodular Abdomen Mass with hemorrhagic spots in the anterior mesentery of the small intestines.
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patient has been followed for almost a year and a follow
up abdominal scan was conducted, all indicating the
patient was free from any signs of recurrence including
the palpitations and diaphoresis.
Discussion
Neural crest cells give rise to the parenchymal cells of
the paraganglia and other elements of the autonomic
nervous system. These neural crest cells have the ability
to migrate to various regions along the paravertebral
and para-aortic axis, while remaining in close relation to
the sympathetic nervous system. They extend to various
places, anywhere from the neck to the base of the pelvis
[4]. In rare occasions, paragangliomas have been identi-
fied in areas where chromaffin tissue has not yet been
characterized, such as the genitourinary tract, spermatic
cord, sacro-coccygeal area, anus, renal capsule, broad
ligament, ovary and vaginal wall and can only be
explained by the migratory property of the neural crest
cells [5]. It has been hypothesized that tumors such as
the one presented in this case report derive from the
mesenteric paraganglionic tissue, which arises from ver-
tebral migration from the root of the superior mesen-
teric artery [4].
Diagnosing paragangliomas, and in particular those of
the mesentery, can be achieved via biochemistry and/or
imagery. Given the capacity of a paraganglioma to
secrete catecholamines, plasma or urinary metane-
phrines have been described in the literature as a very
sensitive technique. Unfortunately the secreting property
is only found in 25% of mesenteric paragangliomas [1].
Anatomical imagery with US/CT/MRI are equally as
effective in identifying these abdominal masses. In addi-
tion, specific functional imaging with metaiodo-benzyl-
guanidine scintigraphy or PET imaging with 6 [
18F]
fluoro-DOPA help identify and characterize the extent
of the mass as well as the staging [6]. These techniques
are then followed up with seemingly essential laparo-
scopic exploration and biopsy [7]. Finally, tumor resec-
tion is the form of treatment that has achieved the best
results. Throughout all the cases described in the litera-
ture, none described any recurrence post-excision of the
mass, but median follow-up was relatively short [Table
1]. Chemotherapy and radiotherapy have not demon-
strated convincing results for patients with unresectable
or metastatic disease. Its involvement remains palliative,
as there is no current evidence of increased survival
using these modalities [6]. Treatment with radiolabelled
MIBG is gaining popularity given its avidity for the
chromaffin cell tumors and in particular their metastases
[8]. The literature stipulates that while
131I-MIBG is not
a curative therapy, its involvement as an adjuvant to
surgical resection as well as the possibility of a synergis-
tic effect with chemotherapy seem promising and are
venues to be explored in the near future [9]. Radioactive
Figure 4 Immunohistochemical staining of the resected specimen. Immunohistochemical staining positive for protein S100 demonstrating
sustentacular cells around the periphery of the cell nests and supporting the diagnosis of paraganglioma.
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cal to be considered [6]. Focus has now shifted to speci-
fic molecular targets involved in the malignant
transformation of chromaffin cell tumors, and its devel-
opment has shown signs of promise, yet development in
these areas is still necessary [10].
With the exception of a single case documenting liver
metastases, and to the best of our knowledge, this is the
first case documenting regional lymph node metastases.
As a result, this case can further be classified as one of
malignant paraganglioma. This comes to no surprise
given malignant chromaffin cell tumor have been docu-
mented to metastasize to local lymph nodes, bone liver
and lung [6].
Conclusion
Paragangliomas represent only 10% of chromaffin tissue
tumors and the mesenteric form seems to be a rare
occurrence, but should be among the preoperative dif-
ferential diagnosis of abdominal masses of unknown
etiology. The diagnosis is best achieved by imagery and
laparoscopic exploration. Metastases although extremely
rare, must be taken into account. Finally resection has
proven to be the most effective method of treatment,
while chemotherapy and radiotherapy have both been
proven ineffective in previous cases.
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